![Emma Tallantyre](https://profiles-cardiff.imgix.net/attachments/2615?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Emma Tallantyre
(hi/ei)
- Ar gael fel goruchwyliwr ôl-raddedig
Timau a rolau for Emma Tallantyre
Athro, Is-adran Meddygaeth Seicolegol a Niwrowyddorau Clinigol
Trosolwg
Graddiais o'r ysgol feddygol ym Mhrifysgol Nottingham yn 2002. Ymgymerais â'm hyfforddiant meddygol a niwrolegol ôl-raddedig yn Nottingham, Derby, Awstralia a De Cymru. Fel cymrawd ymchwil MRC, cwblheais PhD yn ymchwilio i ddelweddu (canolfan MR Syr Peter Mansfield) a niwropatholeg (Prifysgol Nottingham) o sglerosis ymledol (MS).
Rwyf wedi bod yn ymwneud â gofal clinigol pobl ag MS ers 2006. Cwblheais fy hyfforddiant clinigol yn 2015 a deuthum yn Uwch Ddarlithydd Clinigol mewn Niwroleg yn 2018, ac yn Ddarllenydd Clinigol yn 2022 ac yn Athro yn 2026. Mae gen i gontract er anrhydedd i weithio fel Niwrolegydd Ymgynghorol yn Uned Niwrolidiol Helen Durham yn Ysbyty Athrofaol Cymru. Fel rhan o'r rôl hon rwy'n rhedeg clinigau MS wythnosol a niwroleg gyffredinol ac yn cyfrannu at ddatblygu gwasanaethau.
Mae fy niddordebau ymchwil presennol yn canolbwyntio ar ganlyniadau clefyd niwrollid. Rwy'n ymwneud â threialon clinigol sy'n ymchwilio i'r dulliau triniaeth gorau posibl mewn sglerosis ymledol. Mae gen i ddiddordeb mewn cyfuno data clinigol yn y byd go iawn gyda data biolegol a delweddu cysylltiedig i gryfhau rhagfynegiadau canlyniadau a gwella dyluniad treialon. Mae gen i ddiddordeb hefyd mewn cynnwys cleifion a'r cyhoedd yn natblygiad astudiaethau ymchwil clinigol.
Cyhoeddiad
2026
- Valero-Hernandez, E. et al., 2026. Lymphocytosis as a biomarker for natalizumab treatment response in multiple sclerosis: The link with anti-drug antibodies. Multiple Sclerosis Journal (10.1177/13524585261495351)
- Gilmartin, C. G. et al., 2026. MRI before CSF: prospective evidence that the 2024 McDonald criteria reduce lumbar punctures. Multiple Sclerosis and Related Disorders 107984. (10.1016/j.msard.2026.107984)
- Arun, T. et al., 2026. Non-invasive biomarkers for neurosarcoidosis: Complement activation as a tool for diagnosis and prognosis. Journal of Neuroimmunology 418 578969. (10.1016/j.jneuroim.2026.578969)
- O'Nions, E. et al., 2026. EQUITY-MS: Evaluating the quality of investigation and treatment of multiple sclerosis using data from five specialist neurology centres in the United Kingdom: study protocol. BMJ Open 16 (9) e114912. (10.1136/bmjopen-2025-114912)
- das Nair, R. et al., 2026. Neuropsychological evaluation and rehabilitation in multiple sclerosis (NEuRoMS): A mixed-methods, multi-centre feasibility randomised controlled trial. Multiple Sclerosis Journal – Experimental, Translational and Clinical 12 (3)(10.1177/20552173261487853)
- Manzano, C. L. et al., 2026. Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model. Health Technology Assessment 30 (60), pp.1-290. (10.3310/GJHT1811)
- Abbadessa, G. et al., 2026. Genetic subtypes of multiple sclerosis severity are uncoupled from inflammatory lesion burden. Acta Neuropathologica 152 24. (10.1007/s00401-026-03062-x)
- Witts, J. et al., 2026. Multiple Sclerosis and ethnicity in Wales: a SAIL Databank study [Abstract]. International Journal of Population Data Science 11 (5), pp.3642. (10.23889/ijpds.v11i5.3642)
- Tallantyre, E. et al. 2026. Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS). Multiple Sclerosis Journal 32 (7), pp.722-736. (10.1177/13524585261449988)
- Tallantyre, E. C. , Apap Mangion, S. and Teunissen, C. E. 2026. A framework for blood biomarker discovery in MS. Multiple Sclerosis Journal 32 (7), pp.661-669. (10.1177/13524585261432045)
- Lopez Manzano, C. et al., 2026. Defining activity‐based subgroups in multiple sclerosis: a review and framework proposal. European Journal of Neurology 33 (6) e70663. (10.1111/ene.70663)
- Kreft, K. L. et al. 2026. Genetic subtypes associated with multiple sclerosis severity and response to treatment. Journal of Neurology, Neurosurgery and Psychiatry 97 (5), pp.413-421. (10.1136/jnnp-2025-337337)
- Malhotra, P. et al., 2026. Multi-arm multi-stage platform trials for neurological disease: accelerating progress [Comment]. The Lancet 407 (10544), pp.2154-2156. (10.1016/s0140-6736(26)00978-5)
- Gelissen, L. M. et al., 2026. Clinical implications of natalizumab Fab-arm exchange in patients with multiple sclerosis. Frontiers in Immunology 17 1796273. (10.3389/fimmu.2026.1796273)
- Meir Jacobs, B. et al., 2026. Genetic determinants of multiple sclerosis susceptibility in people from diverse ancestral backgrounds. Neurology 106 (7) e214708. (10.1212/wnl.0000000000214708)
- Voase, S. et al., 2026. MOGAD in South Wales: Diagnostic evolution and disease epidemiology. European Journal of Neurology 33 (2) e70502. (10.1111/ene.70502)
2025
- Sadek, A. et al., 2025. Discrete event simulation and treatment sequencing cost-effectiveness model in second-line highly active relapse remitting multiple sclerosis for a NICE multiple technology appraisal. Presented at: ISPOR Europe 2025 Glasgow, Scotland 09-12 November 2025. Vol. 28.Vol. Supp 1. Elsevier(10.1016/j.jval.2025.09.720)
- Clarke, M. et al., 2025. 197 Diagnosing multiple sclerosis using the central vein sign: validating the proposed lesion assessment criteria [Abstract]. Journal of Neurology, Neurosurgery and Psychiatry 96 A61. (10.1136/jnnp-2025-ABN.197)
- Kremler, C. et al., 2025. Real world outcomes of alemtuzumab in relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 96 , pp.A42.3. (10.1136/jnnp-2025-ABN.139)
- Upcott, M. et al., 2025. 19 Transcriptional risk scores identify subgroups of multiple sclerosis patients more accurately than polygenic risk scores [Abstract]. Journal of Neurology, Neurosurgery and Psychiatry 96 A6. (10.1136/jnnp-2025-abn.19)
- Wood, C. et al., 2025. 47 Multiple sclerosis and seizures: clinical, diagnostic and therapeutic correlations [Abstract]. Journal of Neurology, Neurosurgery and Psychiatry 96 A15. (10.1136/jnnp-2025-abn.47)
- Griffiths, L. et al., 2025. Sterol imbalances and cholesterol-24-hydroxylase dysregulation is linked to the underlying progression of multiple sclerosis. Brain Pathology 35 (5) e70001. (10.1111/bpa.70001)
- Dobson, R. et al., 2025. Approach to JCV testing with natalizumab biosimilar: a UK consensus statement. Multiple Sclerosis and Related Disorders 100 106541. (10.1016/j.msard.2025.106541)
- Tallantyre, E. C. et al. 2025. Home-sampling of B cells using quantitative dried blood spots to enable tailored therapeutic re-dosing of anti-CD20 therapies. Multiple Sclerosis Journal 31 (8), pp.1007-1010. (10.1177/13524585251330962)
- Finlayson, M. et al., 2025. Designing well-being intervention trials for people with progressive multiple sclerosis: the importance of understanding usual care comparators [Editorial]. International Journal of MS Care 27 , pp.T27-T31. (10.7224/1537-2073.2024-099)
- Allen, C. M. et al., 2025. Comparison of the diagnostic performance of the central vein sign and CSF oligoclonal bands supporting the diagnosis of multiple sclerosis. Neurology Open Access 1 (2) e000021. (10.1212/wn9.0000000000000017)
- Androdias, G. et al., 2025. De-escalating and discontinuing disease-modifying therapies in multiple sclerosis. Brain 148 (5), pp.1459-1478. (10.1093/brain/awae409)
- Wood, C. et al., 2025. Multiple sclerosis and seizures: clinical, diagnostic and therapeutic correlations. Brain and Behavior 15 (5) e70511. (10.1002/brb3.70511)
- Davies, L. et al., 2025. Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis. Journal of Neurology 272 415. (10.1007/s00415-025-13133-w)
2024
- Arun, T. et al., 2024. Assessing the landscape and charting paths: UK neurology trainees' opinions on neuroinflammation subspecialty. Multiple Sclerosis and Related Disorders 92 106144. (10.1016/j.msard.2024.106144)
- Coerver, E. et al., 2024. The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis. Multiple Sclerosis and Related Disorders 91 105900. (10.1016/j.msard.2024.105900)
- Nicholas, R. et al., 2024. Algorithmic approach to finding people with multiple sclerosis using routine healthcare data in Wales. Journal of Neurology, Neurosurgery & Psychiatry 96 (11), pp.1032-1035. (10.1136/jnnp-2024-333532)
- Gelissen, L. M. et al., 2024. Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration. Multiple Sclerosis and Related Disorders 90 105796. (10.1016/j.msard.2024.105796)
- Roos, I. et al., 2024. Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal 30 (9), pp.1163-1175. (10.1177/13524585241267211)
- Tallantyre, E. C. et al. 2024. Real world persistence of multiple sclerosis disease modifying therapies. European Journal of Neurology 31 (7) e16289. (10.1111/ene.16289)
- De Dios perez, B. et al., 2024. The Impact of Covid-19 on the employment of people with multiple sclerosis: A multi-methods study. International Journal of MS Care 26 (Q3), pp.174-186. (10.7224/1537-2073.2023-049)
- Uzochukwu, E. C. et al. 2024. Modelling disease progression of Multiple Sclerosis in a South Wales cohort. Neuroepidemiology 58 (3), pp.218-226. (10.1159/000536427)
- Nasir, M. et al., 2024. Impact of rituximab treatment regime on time to relapse in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders 85 105528. (10.1016/j.msard.2024.105528)
- Kreft, K. L. et al. 2024. Relevance of multiple sclerosis severity genotype in predicting disease course: A real-world cohort. Annals of Neurology 95 (3), pp.459-470. (10.1002/ana.26831)
- Kodosaki, E. et al. 2024. Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes. Journal of Neuroinflammation 21 (1) 52. (10.1186/s12974-024-03036-4)
2023
- Papathanasiou, A. et al., 2023. Real world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: A retrospective multicentre cohort study. Neurological Sciences 44 , pp.3629-3635. (10.1007/s10072-023-06838-1)
- Zaloum, S. et al., 2023. Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination. Multiple Sclerosis Journal 29 (8), pp.979-989. (10.1177/13524585231185247)
- Htet, Z. M. and Tallantyre, E. 2023. Optic neuritis and MOGAD. Journal of Neurology 270 (6), pp.3278–3279. (10.1007/s00415-023-11738-7)
- Jacobs, B. M. et al., 2023. The ADAMS project - a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the United Kingdom. BMJ Open 13 e071656. (10.1136/bmjopen-2023-071656)
- Morgan, A. , Tallantyre, E. and Ontaneda, D. 2023. The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis. Expert Review of Neurotherapeutics 23 (5), pp.433-444. (10.1080/14737175.2023.2208347)
- Harding, K. E. et al., 2023. Contemporary study of multiple sclerosis disability in South East Wales. Journal of Neurology, Neurosurgery and Psychiatry 94 (4), pp.272-279. (10.1136/jnnp-2022-330013)
- Garjani, A. et al., 2023. Decentralised clinical trials in multiple sclerosis research. Multiple Sclerosis Journal 29 (3), pp.317-325. (10.1177/13524585221100401)
2022
- Beesley, R. et al., 2022. Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviours and access to disease-modifying therapies. Multiple Sclerosis and Related Disorders 68 104121. (10.1016/j.msard.2022.104121)
- Cauchi, M. et al. 2022. Multiple Sclerosis and the risk of infection: Association of British Neurologists consensus guideline. Practical Neurology 22 (5), pp.344-357. (10.1136/practneurol-2022-003370)
- Tallantyre, E. C. et al. 2022. Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis.. Multiple Sclerosis and Related Disorders 64 103937. (10.1016/j.msard.2022.103937)
- Tallantyre, E. C. 2022. Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk ? No. Multiple Sclerosis Journal 28 (8), pp.1175-1177. (10.1177/13524585221091404)
- Garjani, A. et al., 2022. Mental health of people with multiple sclerosis during the COVID-19 outbreak: a prospective cohort and cross-sectional case-control study of the UK MS Register. Multiple Sclerosis Journal 28 (7), pp.1060-1071. (10.1177/13524585211020435)
- Topcu, G. et al., 2022. Neuropsychological evaluation and rehabilitation in multiple sclerosis (NEuRoMS): Protocol for a mixed-methods, multi-centre feasibility randomised controlled trial. Pilot and Feasibility Studies 8 123. (10.1186/s40814-022-01073-5)
- Allman, M. , Tallantyre, E. and Robertson, N. P. 2022. Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies. Journal of Neurology 269 (4), pp.2259-2261. (10.1007/s00415-022-11053-7)
- Wood, C. H. et al. 2022. Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate. Multiple Sclerosis and Related Disorders 58 103492. (10.1016/j.msard.2022.103492)
- Tallantyre, E. et al. 2022. COVID-19 vaccine response in people with multiple sclerosis. Annals of Neurology 91 (1), pp.89-100. (10.1002/ana.26251)
- Busse, M. et al. 2022. A web-based life-style, exercise and activity intervention for people with progressive multiple sclerosis results of a single-arm feasibility study. Multiple Sclerosis and Related Disorders 57 103388. (10.1016/j.msard.2021.103388)
2021
- Middleton, R. M. et al., 2021. COVID-19 in Multiple Sclerosis: clinically reported outcomes from the UK Multiple Sclerosis Register. Multiple Sclerosis and Related Disorders 56 103317. (10.1016/j.msard.2021.103317)
- Fernandes, L. et al., 2021. The contemporary role of MRI in the monitoring and management of people with multiple sclerosis in the UK. Multiple Sclerosis and Related Disorders 55 103190. (10.1016/j.msard.2021.103190)
- Chamberland, M. et al. 2021. Beyond lesion-load: tractometry-based metrics for characterizing white matter lesions within fibre pathways. Presented at: MICCAI 2020 International Workshop on Computational Diffusion MRI (CDMRI 2020) Virtual 8 October 2020. Published in: Gyori, N. et al., Computational Diffusion MRI: International MICCAI Workshop, Lima, Peru, October 2020. Mathematics and Visualization Springer. , pp.227-237. (10.1007/978-3-030-73018-5_18)
- Winter, M. et al. 2021. Tract-specific MRI measures explain learning and recall differences in multiple sclerosis. Brain Communications 3 (2) fcab065. (10.1093/braincomms/fcab065)
- Garjani, A. et al., 2021. COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies. Multiple Sclerosis and Related Disorders 52 102939. (10.1016/j.msard.2021.102939)
- Hares, K. et al., 2021. KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosis. Journal of Neurology 268 , pp.2175-2184. (10.1007/s00415-020-10373-w)
- MacIver, C. L. , Ebden, S. and Tallantyre, E. C. 2021. MRI: how to understand it. Practical Neurology 21 (3), pp.216-224. (10.1136/practneurol-2020-002905)
- Lipp, I. et al. 2021. Predictors of training-related improvement in visuomotor performance in patients with multiple sclerosis: a behavioural and MRI study. Multiple Sclerosis 7 (7), pp.1088-1101. (10.1177/1352458520943788)
- Latchem-Hastings, J. et al. 2021. Lifestyle, exercise and activity package for people living with progressive multiple sclerosis (LEAP-MS): protocol for a single-arm feasibility study. Pilot and Feasibility Studies 7 111. (10.1186/s40814-021-00852-w)
- Tallantyre, E. et al. 2021. Neurological updates: neurological complications of CAR-T therapy. Journal of Neurology 268 , pp.1544-1554. (10.1007/s00415-020-10237-3)
- Busse, M. et al. 2021. A web-based physical activity intervention for people with progressive Multiple Sclerosis: application of consensus-based intervention development guidance. BMJ Open 11 (3) e045378. (10.1136/bmjopen-2020-045378)
- Evangelou, N. et al., 2021. Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register. Journal of Neurology, Neurosurgery and Psychiatry 92 , pp.107-109. (10.1136/jnnp-2020-324449)
- Allen-Philbey, K. et al., 2021. Subcutaneous cladribine to treat multiple sclerosis: Experience in 208 patients. Therapeutic Advances in Neurological Disorders 14 , pp.1-16. (10.1177/17562864211057661)
2020
- Zelek, W. M. et al. 2020. Cerebrospinal fluid complement system biomarkers in demyelinating disease. Multiple Sclerosis 26 (14), pp.1929-1937. (10.1177/1352458519887905)
- Anderson, V. et al. 2020. Serum neurofilament-light concentration and real-world outcome in MS. Journal of the Neurological Sciences 417 117079. (10.1016/j.jns.2020.117079)
- Ontaneda, D. et al., 2020. Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. Contemporary Clinical Trials 95 (10.1016/j.cct.2020.106009)
- Saxena, G. et al., 2020. Detecting and predicting neutralization of alemtuzumab responses in multiple sclerosis. Neurology, Neuroimmunology and Neuroinflammation 7 (4) e767. (10.1212/NXI.0000000000000767)
- Tallantyre, E. et al. 2020. Eligibility and implementation of disease-modifying therapy for primary progressive multiple sclerosis in a UK cohort. Multiple Sclerosis and Related Disorders 42 102056. (10.1016/j.msard.2020.102056)
- Tallantyre, E. et al. 2020. Achieving effective patient and public involvement in international clinical trials in neurology. Neurology 10 (3), pp.265-272. (10.1212/CPJ.0000000000000739)
- Lipp, I. et al. 2020. Tractography in the presence of multiple sclerosis lesions. NeuroImage 209 116471. (10.1016/j.neuroimage.2019.116471)
- Allen, C. M. et al., 2020. Clinical observation during alemtuzumab administration. Multiple Sclerosis and Related Disorders 37 101412. (10.1016/j.msard.2019.101412)
2019
- Davda, N. , Tallantyre, E. and Robertson, N. P. 2019. Early MRI predictors of prognosis in multiple sclerosis. Journal of Neurology 266 (12), pp.3171-3173. (10.1007/s00415-019-09589-2)
- Abdullah, A. A. N. and Tallantyre, E. 2019. HSV-2 radiculitis: An unusual presentation mere days after genital infection. Clinical Neurology and Neurosurgery 185 105429. (10.1016/j.clineuro.2019.105429)
- Ontaneda, D. et al., 2019. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurology 18 (10), pp.973-980. (10.1016/S1474-4422(19)30151-6)
- Castle, D. et al. 2019. Using biomarkers to predict clinical outcomes in multiple sclerosis. Practical Neurology 19 (4), pp.342-349. (10.1136/practneurol-2018-002000)
- Lipp, I. et al. 2019. Comparing MRI metrics to quantify white matter microstructural damage in multiple sclerosis. Human Brain Mapping 40 (10), pp.2917-2932. (10.1002/hbm.24568)
- Harding, K. et al. 2019. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurology 76 (5), pp.536-541. (10.1001/jamaneurol.2018.4905)
- Whittam, D. H. et al., 2019. Rituximab in neurological disease: principles, evidence and practice. Practical Neurology 19 (1), pp.5-10. (10.1136/practneurol-2018-001899)
2018
- Robertson, J. and Tallantyre, E. 2018. Nerve sheath tumours. Journal of Neurology 265 (12), pp.3034-3035. (10.1007/s00415-018-9098-y)
- Tallantyre, E. C. , Robertson, N. P. and Jolles, S. 2018. Secondary antibody deficiency in neurology. Current Opinion in Allergy and Clinical Immunology 18 (6), pp.481-488. (10.1097/ACI.0000000000000485)
- Beesley, R. et al., 2018. Impact of the 2017 revisions to McDonald criteria on the diagnosis of Multiple Sclerosis. Multiple Sclerosis 24 (13), pp.1786-1787. (10.1177/1352458518778007)
- Harding, K. et al. 2018. A contemporary study of mortality in the multiple sclerosis population of south east Wales. Multiple Sclerosis and Related Disorders 25 , pp.186-191. (10.1016/j.msard.2018.08.001)
- Tallantyre, E. C. et al. 2018. How common is truly benign MS in a UK population?. Journal of Neurology, Neurosurgery and Psychiatry 90 , pp.522-528. (10.1136/jnnp-2018-318802)
- Alsaeed, M. et al., 2018. Multiple sclerosis: long-term outcomes in ethnic minorities. analysis of a UK population-based registry. European Journal of Neurology 25 (4), pp.701-704. (10.1111/ene.13571)
- Tallantyre, E. et al. 2018. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. Journal of Neurology 265 (5), pp.1115-1122. (10.1007/s00415-018-8812-0)
2017
- Willis, M. et al. 2017. An observational study of alemtuzumab following fingolimod for multiple sclerosis. Neuroimmunology and Neuroinflammation 4 (2) E320. (10.1212/NXI.0000000000000320)
2016
- Tallantyre, E. C. and Robertson, N. P. 2016. Continuous evolution of magnetic resonance imaging in multiple sclerosis. Journal of Neurology 263 (4), pp.835-837. (10.1007/s00415-016-8099-y)
- Tallantyre, E. C. , Wardle, M. and Robertson, N. 2016. How to run a multiple sclerosis relapse clinic. Practical Neurology 16 (1), pp.62-69. (10.1136/practneurol-2015-001214)
2015
- Thomas, R. H. et al. 2015. Why neurology? The career choices of current UK neurology trainees [Conference Abstract]. Journal of Neurology, Neurosurgery & Psychiatry 86 (11), pp.e4. 042. (10.1136/jnnp-2015-312379.42)
- Williams, O. , Tallantyre, E. C. and Robertson, N. 2015. Traumatic brain injury: pathophysiology, clinical outcome and treatment. Journal of Neurology 262 (5), pp.1394-1396. (10.1007/s00415-015-7741-4)
- Tallantyre, E. et al. 2015. The aetiology of acute neurological decline in multiple sclerosis: Experience from an open-access clinic. Multiple Sclerosis Journal 21 (1), pp.67-75. (10.1177/1352458514538333)
- Tallantyre, E. C. and Robertson, N. 2015. Acute stroke management. Journal of Neurology 262 (1), pp.239-242. (10.1007/s00415-014-7607-1)
2013
- Tallantyre, E. C. and Robertson, N. 2013. Autism and intellectual disability. Journal of Neurology 260 (3), pp.936-939. (10.1007/s00415-013-6861-y)
Cynadleddau
- Sadek, A. et al., 2025. Discrete event simulation and treatment sequencing cost-effectiveness model in second-line highly active relapse remitting multiple sclerosis for a NICE multiple technology appraisal. Presented at: ISPOR Europe 2025 Glasgow, Scotland 09-12 November 2025. Vol. 28.Vol. Supp 1. Elsevier(10.1016/j.jval.2025.09.720)
- Chamberland, M. et al. 2021. Beyond lesion-load: tractometry-based metrics for characterizing white matter lesions within fibre pathways. Presented at: MICCAI 2020 International Workshop on Computational Diffusion MRI (CDMRI 2020) Virtual 8 October 2020. Published in: Gyori, N. et al., Computational Diffusion MRI: International MICCAI Workshop, Lima, Peru, October 2020. Mathematics and Visualization Springer. , pp.227-237. (10.1007/978-3-030-73018-5_18)
Erthyglau
- Valero-Hernandez, E. et al., 2026. Lymphocytosis as a biomarker for natalizumab treatment response in multiple sclerosis: The link with anti-drug antibodies. Multiple Sclerosis Journal (10.1177/13524585261495351)
- Gilmartin, C. G. et al., 2026. MRI before CSF: prospective evidence that the 2024 McDonald criteria reduce lumbar punctures. Multiple Sclerosis and Related Disorders 107984. (10.1016/j.msard.2026.107984)
- Arun, T. et al., 2026. Non-invasive biomarkers for neurosarcoidosis: Complement activation as a tool for diagnosis and prognosis. Journal of Neuroimmunology 418 578969. (10.1016/j.jneuroim.2026.578969)
- O'Nions, E. et al., 2026. EQUITY-MS: Evaluating the quality of investigation and treatment of multiple sclerosis using data from five specialist neurology centres in the United Kingdom: study protocol. BMJ Open 16 (9) e114912. (10.1136/bmjopen-2025-114912)
- das Nair, R. et al., 2026. Neuropsychological evaluation and rehabilitation in multiple sclerosis (NEuRoMS): A mixed-methods, multi-centre feasibility randomised controlled trial. Multiple Sclerosis Journal – Experimental, Translational and Clinical 12 (3)(10.1177/20552173261487853)
- Manzano, C. L. et al., 2026. Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model. Health Technology Assessment 30 (60), pp.1-290. (10.3310/GJHT1811)
- Abbadessa, G. et al., 2026. Genetic subtypes of multiple sclerosis severity are uncoupled from inflammatory lesion burden. Acta Neuropathologica 152 24. (10.1007/s00401-026-03062-x)
- Witts, J. et al., 2026. Multiple Sclerosis and ethnicity in Wales: a SAIL Databank study [Abstract]. International Journal of Population Data Science 11 (5), pp.3642. (10.23889/ijpds.v11i5.3642)
- Tallantyre, E. et al. 2026. Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS). Multiple Sclerosis Journal 32 (7), pp.722-736. (10.1177/13524585261449988)
- Tallantyre, E. C. , Apap Mangion, S. and Teunissen, C. E. 2026. A framework for blood biomarker discovery in MS. Multiple Sclerosis Journal 32 (7), pp.661-669. (10.1177/13524585261432045)
- Lopez Manzano, C. et al., 2026. Defining activity‐based subgroups in multiple sclerosis: a review and framework proposal. European Journal of Neurology 33 (6) e70663. (10.1111/ene.70663)
- Kreft, K. L. et al. 2026. Genetic subtypes associated with multiple sclerosis severity and response to treatment. Journal of Neurology, Neurosurgery and Psychiatry 97 (5), pp.413-421. (10.1136/jnnp-2025-337337)
- Malhotra, P. et al., 2026. Multi-arm multi-stage platform trials for neurological disease: accelerating progress [Comment]. The Lancet 407 (10544), pp.2154-2156. (10.1016/s0140-6736(26)00978-5)
- Gelissen, L. M. et al., 2026. Clinical implications of natalizumab Fab-arm exchange in patients with multiple sclerosis. Frontiers in Immunology 17 1796273. (10.3389/fimmu.2026.1796273)
- Meir Jacobs, B. et al., 2026. Genetic determinants of multiple sclerosis susceptibility in people from diverse ancestral backgrounds. Neurology 106 (7) e214708. (10.1212/wnl.0000000000214708)
- Voase, S. et al., 2026. MOGAD in South Wales: Diagnostic evolution and disease epidemiology. European Journal of Neurology 33 (2) e70502. (10.1111/ene.70502)
- Clarke, M. et al., 2025. 197 Diagnosing multiple sclerosis using the central vein sign: validating the proposed lesion assessment criteria [Abstract]. Journal of Neurology, Neurosurgery and Psychiatry 96 A61. (10.1136/jnnp-2025-ABN.197)
- Kremler, C. et al., 2025. Real world outcomes of alemtuzumab in relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 96 , pp.A42.3. (10.1136/jnnp-2025-ABN.139)
- Upcott, M. et al., 2025. 19 Transcriptional risk scores identify subgroups of multiple sclerosis patients more accurately than polygenic risk scores [Abstract]. Journal of Neurology, Neurosurgery and Psychiatry 96 A6. (10.1136/jnnp-2025-abn.19)
- Wood, C. et al., 2025. 47 Multiple sclerosis and seizures: clinical, diagnostic and therapeutic correlations [Abstract]. Journal of Neurology, Neurosurgery and Psychiatry 96 A15. (10.1136/jnnp-2025-abn.47)
- Griffiths, L. et al., 2025. Sterol imbalances and cholesterol-24-hydroxylase dysregulation is linked to the underlying progression of multiple sclerosis. Brain Pathology 35 (5) e70001. (10.1111/bpa.70001)
- Dobson, R. et al., 2025. Approach to JCV testing with natalizumab biosimilar: a UK consensus statement. Multiple Sclerosis and Related Disorders 100 106541. (10.1016/j.msard.2025.106541)
- Tallantyre, E. C. et al. 2025. Home-sampling of B cells using quantitative dried blood spots to enable tailored therapeutic re-dosing of anti-CD20 therapies. Multiple Sclerosis Journal 31 (8), pp.1007-1010. (10.1177/13524585251330962)
- Finlayson, M. et al., 2025. Designing well-being intervention trials for people with progressive multiple sclerosis: the importance of understanding usual care comparators [Editorial]. International Journal of MS Care 27 , pp.T27-T31. (10.7224/1537-2073.2024-099)
- Allen, C. M. et al., 2025. Comparison of the diagnostic performance of the central vein sign and CSF oligoclonal bands supporting the diagnosis of multiple sclerosis. Neurology Open Access 1 (2) e000021. (10.1212/wn9.0000000000000017)
- Androdias, G. et al., 2025. De-escalating and discontinuing disease-modifying therapies in multiple sclerosis. Brain 148 (5), pp.1459-1478. (10.1093/brain/awae409)
- Wood, C. et al., 2025. Multiple sclerosis and seizures: clinical, diagnostic and therapeutic correlations. Brain and Behavior 15 (5) e70511. (10.1002/brb3.70511)
- Davies, L. et al., 2025. Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis. Journal of Neurology 272 415. (10.1007/s00415-025-13133-w)
- Arun, T. et al., 2024. Assessing the landscape and charting paths: UK neurology trainees' opinions on neuroinflammation subspecialty. Multiple Sclerosis and Related Disorders 92 106144. (10.1016/j.msard.2024.106144)
- Coerver, E. et al., 2024. The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis. Multiple Sclerosis and Related Disorders 91 105900. (10.1016/j.msard.2024.105900)
- Nicholas, R. et al., 2024. Algorithmic approach to finding people with multiple sclerosis using routine healthcare data in Wales. Journal of Neurology, Neurosurgery & Psychiatry 96 (11), pp.1032-1035. (10.1136/jnnp-2024-333532)
- Gelissen, L. M. et al., 2024. Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration. Multiple Sclerosis and Related Disorders 90 105796. (10.1016/j.msard.2024.105796)
- Roos, I. et al., 2024. Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal 30 (9), pp.1163-1175. (10.1177/13524585241267211)
- Tallantyre, E. C. et al. 2024. Real world persistence of multiple sclerosis disease modifying therapies. European Journal of Neurology 31 (7) e16289. (10.1111/ene.16289)
- De Dios perez, B. et al., 2024. The Impact of Covid-19 on the employment of people with multiple sclerosis: A multi-methods study. International Journal of MS Care 26 (Q3), pp.174-186. (10.7224/1537-2073.2023-049)
- Uzochukwu, E. C. et al. 2024. Modelling disease progression of Multiple Sclerosis in a South Wales cohort. Neuroepidemiology 58 (3), pp.218-226. (10.1159/000536427)
- Nasir, M. et al., 2024. Impact of rituximab treatment regime on time to relapse in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders 85 105528. (10.1016/j.msard.2024.105528)
- Kreft, K. L. et al. 2024. Relevance of multiple sclerosis severity genotype in predicting disease course: A real-world cohort. Annals of Neurology 95 (3), pp.459-470. (10.1002/ana.26831)
- Kodosaki, E. et al. 2024. Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes. Journal of Neuroinflammation 21 (1) 52. (10.1186/s12974-024-03036-4)
- Papathanasiou, A. et al., 2023. Real world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: A retrospective multicentre cohort study. Neurological Sciences 44 , pp.3629-3635. (10.1007/s10072-023-06838-1)
- Zaloum, S. et al., 2023. Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination. Multiple Sclerosis Journal 29 (8), pp.979-989. (10.1177/13524585231185247)
- Htet, Z. M. and Tallantyre, E. 2023. Optic neuritis and MOGAD. Journal of Neurology 270 (6), pp.3278–3279. (10.1007/s00415-023-11738-7)
- Jacobs, B. M. et al., 2023. The ADAMS project - a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the United Kingdom. BMJ Open 13 e071656. (10.1136/bmjopen-2023-071656)
- Morgan, A. , Tallantyre, E. and Ontaneda, D. 2023. The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis. Expert Review of Neurotherapeutics 23 (5), pp.433-444. (10.1080/14737175.2023.2208347)
- Harding, K. E. et al., 2023. Contemporary study of multiple sclerosis disability in South East Wales. Journal of Neurology, Neurosurgery and Psychiatry 94 (4), pp.272-279. (10.1136/jnnp-2022-330013)
- Garjani, A. et al., 2023. Decentralised clinical trials in multiple sclerosis research. Multiple Sclerosis Journal 29 (3), pp.317-325. (10.1177/13524585221100401)
- Beesley, R. et al., 2022. Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviours and access to disease-modifying therapies. Multiple Sclerosis and Related Disorders 68 104121. (10.1016/j.msard.2022.104121)
- Cauchi, M. et al. 2022. Multiple Sclerosis and the risk of infection: Association of British Neurologists consensus guideline. Practical Neurology 22 (5), pp.344-357. (10.1136/practneurol-2022-003370)
- Tallantyre, E. C. et al. 2022. Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis.. Multiple Sclerosis and Related Disorders 64 103937. (10.1016/j.msard.2022.103937)
- Tallantyre, E. C. 2022. Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk ? No. Multiple Sclerosis Journal 28 (8), pp.1175-1177. (10.1177/13524585221091404)
- Garjani, A. et al., 2022. Mental health of people with multiple sclerosis during the COVID-19 outbreak: a prospective cohort and cross-sectional case-control study of the UK MS Register. Multiple Sclerosis Journal 28 (7), pp.1060-1071. (10.1177/13524585211020435)
- Topcu, G. et al., 2022. Neuropsychological evaluation and rehabilitation in multiple sclerosis (NEuRoMS): Protocol for a mixed-methods, multi-centre feasibility randomised controlled trial. Pilot and Feasibility Studies 8 123. (10.1186/s40814-022-01073-5)
- Allman, M. , Tallantyre, E. and Robertson, N. P. 2022. Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies. Journal of Neurology 269 (4), pp.2259-2261. (10.1007/s00415-022-11053-7)
- Wood, C. H. et al. 2022. Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate. Multiple Sclerosis and Related Disorders 58 103492. (10.1016/j.msard.2022.103492)
- Tallantyre, E. et al. 2022. COVID-19 vaccine response in people with multiple sclerosis. Annals of Neurology 91 (1), pp.89-100. (10.1002/ana.26251)
- Busse, M. et al. 2022. A web-based life-style, exercise and activity intervention for people with progressive multiple sclerosis results of a single-arm feasibility study. Multiple Sclerosis and Related Disorders 57 103388. (10.1016/j.msard.2021.103388)
- Middleton, R. M. et al., 2021. COVID-19 in Multiple Sclerosis: clinically reported outcomes from the UK Multiple Sclerosis Register. Multiple Sclerosis and Related Disorders 56 103317. (10.1016/j.msard.2021.103317)
- Fernandes, L. et al., 2021. The contemporary role of MRI in the monitoring and management of people with multiple sclerosis in the UK. Multiple Sclerosis and Related Disorders 55 103190. (10.1016/j.msard.2021.103190)
- Winter, M. et al. 2021. Tract-specific MRI measures explain learning and recall differences in multiple sclerosis. Brain Communications 3 (2) fcab065. (10.1093/braincomms/fcab065)
- Garjani, A. et al., 2021. COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies. Multiple Sclerosis and Related Disorders 52 102939. (10.1016/j.msard.2021.102939)
- Hares, K. et al., 2021. KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosis. Journal of Neurology 268 , pp.2175-2184. (10.1007/s00415-020-10373-w)
- MacIver, C. L. , Ebden, S. and Tallantyre, E. C. 2021. MRI: how to understand it. Practical Neurology 21 (3), pp.216-224. (10.1136/practneurol-2020-002905)
- Lipp, I. et al. 2021. Predictors of training-related improvement in visuomotor performance in patients with multiple sclerosis: a behavioural and MRI study. Multiple Sclerosis 7 (7), pp.1088-1101. (10.1177/1352458520943788)
- Latchem-Hastings, J. et al. 2021. Lifestyle, exercise and activity package for people living with progressive multiple sclerosis (LEAP-MS): protocol for a single-arm feasibility study. Pilot and Feasibility Studies 7 111. (10.1186/s40814-021-00852-w)
- Tallantyre, E. et al. 2021. Neurological updates: neurological complications of CAR-T therapy. Journal of Neurology 268 , pp.1544-1554. (10.1007/s00415-020-10237-3)
- Busse, M. et al. 2021. A web-based physical activity intervention for people with progressive Multiple Sclerosis: application of consensus-based intervention development guidance. BMJ Open 11 (3) e045378. (10.1136/bmjopen-2020-045378)
- Evangelou, N. et al., 2021. Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register. Journal of Neurology, Neurosurgery and Psychiatry 92 , pp.107-109. (10.1136/jnnp-2020-324449)
- Allen-Philbey, K. et al., 2021. Subcutaneous cladribine to treat multiple sclerosis: Experience in 208 patients. Therapeutic Advances in Neurological Disorders 14 , pp.1-16. (10.1177/17562864211057661)
- Zelek, W. M. et al. 2020. Cerebrospinal fluid complement system biomarkers in demyelinating disease. Multiple Sclerosis 26 (14), pp.1929-1937. (10.1177/1352458519887905)
- Anderson, V. et al. 2020. Serum neurofilament-light concentration and real-world outcome in MS. Journal of the Neurological Sciences 417 117079. (10.1016/j.jns.2020.117079)
- Ontaneda, D. et al., 2020. Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. Contemporary Clinical Trials 95 (10.1016/j.cct.2020.106009)
- Saxena, G. et al., 2020. Detecting and predicting neutralization of alemtuzumab responses in multiple sclerosis. Neurology, Neuroimmunology and Neuroinflammation 7 (4) e767. (10.1212/NXI.0000000000000767)
- Tallantyre, E. et al. 2020. Eligibility and implementation of disease-modifying therapy for primary progressive multiple sclerosis in a UK cohort. Multiple Sclerosis and Related Disorders 42 102056. (10.1016/j.msard.2020.102056)
- Tallantyre, E. et al. 2020. Achieving effective patient and public involvement in international clinical trials in neurology. Neurology 10 (3), pp.265-272. (10.1212/CPJ.0000000000000739)
- Lipp, I. et al. 2020. Tractography in the presence of multiple sclerosis lesions. NeuroImage 209 116471. (10.1016/j.neuroimage.2019.116471)
- Allen, C. M. et al., 2020. Clinical observation during alemtuzumab administration. Multiple Sclerosis and Related Disorders 37 101412. (10.1016/j.msard.2019.101412)
- Davda, N. , Tallantyre, E. and Robertson, N. P. 2019. Early MRI predictors of prognosis in multiple sclerosis. Journal of Neurology 266 (12), pp.3171-3173. (10.1007/s00415-019-09589-2)
- Abdullah, A. A. N. and Tallantyre, E. 2019. HSV-2 radiculitis: An unusual presentation mere days after genital infection. Clinical Neurology and Neurosurgery 185 105429. (10.1016/j.clineuro.2019.105429)
- Ontaneda, D. et al., 2019. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurology 18 (10), pp.973-980. (10.1016/S1474-4422(19)30151-6)
- Castle, D. et al. 2019. Using biomarkers to predict clinical outcomes in multiple sclerosis. Practical Neurology 19 (4), pp.342-349. (10.1136/practneurol-2018-002000)
- Lipp, I. et al. 2019. Comparing MRI metrics to quantify white matter microstructural damage in multiple sclerosis. Human Brain Mapping 40 (10), pp.2917-2932. (10.1002/hbm.24568)
- Harding, K. et al. 2019. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurology 76 (5), pp.536-541. (10.1001/jamaneurol.2018.4905)
- Whittam, D. H. et al., 2019. Rituximab in neurological disease: principles, evidence and practice. Practical Neurology 19 (1), pp.5-10. (10.1136/practneurol-2018-001899)
- Robertson, J. and Tallantyre, E. 2018. Nerve sheath tumours. Journal of Neurology 265 (12), pp.3034-3035. (10.1007/s00415-018-9098-y)
- Tallantyre, E. C. , Robertson, N. P. and Jolles, S. 2018. Secondary antibody deficiency in neurology. Current Opinion in Allergy and Clinical Immunology 18 (6), pp.481-488. (10.1097/ACI.0000000000000485)
- Beesley, R. et al., 2018. Impact of the 2017 revisions to McDonald criteria on the diagnosis of Multiple Sclerosis. Multiple Sclerosis 24 (13), pp.1786-1787. (10.1177/1352458518778007)
- Harding, K. et al. 2018. A contemporary study of mortality in the multiple sclerosis population of south east Wales. Multiple Sclerosis and Related Disorders 25 , pp.186-191. (10.1016/j.msard.2018.08.001)
- Tallantyre, E. C. et al. 2018. How common is truly benign MS in a UK population?. Journal of Neurology, Neurosurgery and Psychiatry 90 , pp.522-528. (10.1136/jnnp-2018-318802)
- Alsaeed, M. et al., 2018. Multiple sclerosis: long-term outcomes in ethnic minorities. analysis of a UK population-based registry. European Journal of Neurology 25 (4), pp.701-704. (10.1111/ene.13571)
- Tallantyre, E. et al. 2018. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. Journal of Neurology 265 (5), pp.1115-1122. (10.1007/s00415-018-8812-0)
- Willis, M. et al. 2017. An observational study of alemtuzumab following fingolimod for multiple sclerosis. Neuroimmunology and Neuroinflammation 4 (2) E320. (10.1212/NXI.0000000000000320)
- Tallantyre, E. C. and Robertson, N. P. 2016. Continuous evolution of magnetic resonance imaging in multiple sclerosis. Journal of Neurology 263 (4), pp.835-837. (10.1007/s00415-016-8099-y)
- Tallantyre, E. C. , Wardle, M. and Robertson, N. 2016. How to run a multiple sclerosis relapse clinic. Practical Neurology 16 (1), pp.62-69. (10.1136/practneurol-2015-001214)
- Thomas, R. H. et al. 2015. Why neurology? The career choices of current UK neurology trainees [Conference Abstract]. Journal of Neurology, Neurosurgery & Psychiatry 86 (11), pp.e4. 042. (10.1136/jnnp-2015-312379.42)
- Williams, O. , Tallantyre, E. C. and Robertson, N. 2015. Traumatic brain injury: pathophysiology, clinical outcome and treatment. Journal of Neurology 262 (5), pp.1394-1396. (10.1007/s00415-015-7741-4)
- Tallantyre, E. et al. 2015. The aetiology of acute neurological decline in multiple sclerosis: Experience from an open-access clinic. Multiple Sclerosis Journal 21 (1), pp.67-75. (10.1177/1352458514538333)
- Tallantyre, E. C. and Robertson, N. 2015. Acute stroke management. Journal of Neurology 262 (1), pp.239-242. (10.1007/s00415-014-7607-1)
- Tallantyre, E. C. and Robertson, N. 2013. Autism and intellectual disability. Journal of Neurology 260 (3), pp.936-939. (10.1007/s00415-013-6861-y)
Ymchwil
Mae gen i brofiad o ddefnyddio delweddu strwythurol maes uchel i ddelweddu mater gwyn a patholeg mater llwyd yn ymennydd pobl ag MS. Yn ystod fy PhD roeddwn i'n cydberthynas â chanfyddiadau delweddu MR in vivo â'r patholeg niwroddirywiol a welir yn yr ymennydd post mortem a llinynnau asgwrn cefn y rhai sydd ag MS hirsefydlog.
Mae fy niddordebau ymchwil presennol yn canolbwyntio ar ganlyniadau clefyd niwrolididiol. Rwy'n ymwneud â threialon clinigol sy'n ymchwilio i'r dulliau triniaeth gorau posibl mewn sglerosis ymledol. Rwy'n cyfrannu at brosiect epidemiolegol hirsefydlog, gan gasglu data clinigol o garfan o bobl â chlefydau niwrollidiol gan gynnwys MS. Mae gen i ddiddordeb mewn cyfuno'r data clinigol byd go iawn hwn â data biolegol a delweddu cysylltiedig i gryfhau rhagfynegiadau canlyniadau a gwella dyluniad treialon. Mae gen i ddiddordeb hefyd mewn cynnwys cleifion a'r cyhoedd yn natblygiad astudiaethau ymchwil clinigol.
Grantiau a Dyfarniadau
Biofarcwyr protein fel mesurau canlyniadau interim yn OCTOPUS
-
Sefydliad: Cymdeithas MS
Cyfeiriad y sefydliad: Llundain, Lloegr, Prydain Fawr
Dyddiad dechrau: 2026
Math: grant
RHODD i MS blaengar; datrys llwybrau biolegol sy'n arwain at anabledd
Sefydliad: Cymdeithas MS
Cyfeiriad y sefydliad: Llundain, Lloegr, Prydain Fawr
Dyddiad dechrau: 2026
Math: grant
-
FFOCWS-GIG: Fframwaith ar gyfer mOnitoring a gwella Defnydd Clinigol o biodebyg ar draws y GIG
Sefydliad: Sefydliad Cenedlaethol ar gyfer Ymchwil Iechyd a Gofal
Cyfeiriad y sefydliad: Llundain, Prydain Fawr
Dyddiad dechrau: 2026-05-01
Dyddiad gorffen: 2031-04-30
Math: grant
LAU: https://app.dimensions.ai/details/grant/grant.15392838
grant_number: NIHR514756 (https://fundingawards.nihr.ac.uk/award/NIHR514756)
Gwyliadwriaeth o iechyd a heintiau mewn MS sy'n gysylltiedig â therapïau addasu clefydau (SHIELD).
Sefydliad: Cymdeithas MS
Cyfeiriad y sefydliad: Llundain, Lloegr, Prydain Fawr
Dyddiad dechrau: 2025-07
Dyddiad gorffen: 2027-06
Math: grant
Cyflwyno canlyniadau MRI o'r radd flaenaf yn awtomatig i gofnodion gofal iechyd i wella gofal a thrawsnewid ymchwil mewn sglerosis ymledol: astudiaeth beilot.
Sefydliad: Cymdeithas MS
Cyfeiriad y sefydliad: Llundain, Lloegr, Prydain Fawr
Dyddiad dechrau: 2024-10
Dyddiad gorffen: 2026-10
Math: dyfarniad
Cymharu effeithiolrwydd hirdymor dulliau triniaeth cychwynnol ar gyfer sglerosis ymledol sy'n ailwaelu ar atal anabledd
Sefydliad: Sefydliad Ymchwil Canlyniadau sy'n Canolbwyntio ar y Claf
Cyfeiriad y sefydliad: Washington DC, UDA
Dyddiad dechrau: 2025-03-01
Dyddiad gorffen: 2030-02-28
Math: grant
LAU: https://app.dimensions.ai/details/grant/grant.14881045
grant_number: grant.14881045 (https://www.pcori.org/research-results/2025/prevention-disability-relapsing-remitting-multiple-sclerosis)
Pennu Effeithiolrwydd dulliau Dwys Cynnar yn erbyn Cynnydd ar gyfer trin Sglerosis Ymledol Ailwael-Ildio (DELIVER-MS)Sefydliad: Cymdeithas MS Genedlaethol
Cyfeiriad y sefydliad: Dinas Efrog Newydd, UDA
Dyddiad dechrau: 2023
Math: grant
LAU: http://www.deliver-ms.com/
grant_number: SI-1902-33619
Byw'n dda gydag MS blaengar: Rhaglen adsefydlu gymunedol gyfannol wedi'i phersonoli, sy'n canolbwyntio ar nod i wella gweithrediad a lles
Sefydliad: Cynghrair MS Blaengar Ryngwladol
Cyfeiriad y sefydliad: Llundain, Prydain Fawr
Dyddiad dechrau: 2023
Math: grant
Mesurau Canlyniadau a Adroddir gan Gleifion i lunio ymgynghoriadau clinigol: effaith ar foddhad cleifion
Sefydliad: Sefydliad Cymdeithas Diogelu Meddygol
Cyfeiriad y sefydliad: Leeds, Prydain Fawr
Dyddiad dechrau: 2023
Math: grant
Rownd Grant INSPIRE
Sefydliad: Academi'r Gwyddorau Meddygol
Cyfeiriad y sefydliad: Llundain, Prydain Fawr
Dyddiad dechrau: 2022
Math: grant
Biofarcwyr diagnostig a rhagfynegol mewn Neurosarcoidosis a Sglerosis Ymledol: Astudiaeth ddarparSefydliad: Ferblanc
Cyfeiriad y sefydliad: Norwich, Prydain Fawr
Dyddiad dechrau: 2022
Math: grant
grant_number: 20230615
Cais am Simoa HD Analyzer
Sefydliad: Cronfa Seilwaith Ymchwil Prifysgol Caerdydd (RIF).
Cyfeiriad y sefydliad: Caerdydd, Prydain Fawr
Dyddiad dechrau: 2021-09
Math: grant
Modelu cyfoes o ganlyniadau Sglerosis Ymledol mewn poblogaeth yn Ne Cymru.
Sefydliad: Ymddiriedolaeth Wellcome ISSF
Cyfeiriad y sefydliad: Llundain, Prydain Fawr
Dyddiad dechrau: 2019-09
Dyddiad gorffen: 2021-10
Math: grant
Biobancio mewn Astudiaethau Dull Triniaeth mewn MS Relapsing RemittingSefydliad: Cymdeithas Genedlaethol Sglerosis Ymledol
Cyfeiriad y sefydliad: Efrog Newydd, Efrog Newydd, Unol Daleithiau
Dyddiad dechrau: 2019
Math: grant
grant_number: amherthnasol
PENDERFYNOL: Gwneud diagnosis gan ddefnyddio'r arwydd gwythiennau canologSefydliad: NIHR RfPB
Cyfeiriad y sefydliad: Llundain, Prydain Fawr
Dyddiad dechrau: 2019
Math: grant
grant_number: PB-PG-0418-20044
Biofarcwyr diagnostig a rhagfynegol mewn plasma Sglerosis Ymledol: dull sgrinio cynhwysfawr
Sefydliad: Cyngor Ymchwil Feddygol Hyder mewn Cysyniad
Cyfeiriad y sefydliad: Llundain, Prydain Fawr
Dyddiad dechrau: 2019
Math: grant
DELIVER-MS: Pennu effeithiolrwydd dulliau dwys cynnar yn erbyn dwysáu ar gyfer trin MS sy'n ailwaeluSefydliad: Sefydliad Ymchwil Canlyniadau sy'n Canolbwyntio ar y Cleifion (PCORI)
Cyfeiriad y sefydliad: D.C., D.C., UDA
Dyddiad dechrau: 2017
Math: grant
grant_number: R161037047
Pecyn ymarfer corff a gweithgareddau ffordd o fyw i bobl sy'n byw gydag MS blaengarSefydliad: Cymdeithas Sglerosis Ymledol y DU
Cyfeiriad y sefydliad: Llundain, Prydain Fawr
Dyddiad dechrau: 2017
Math: grant
grant_number: 1735
-
Rheoli MS: budd strategaethau cynyddu yn erbyn ymsefydlu mewn therapi modyfying clefydau
Sefydliad: Ymchwil Iechyd a Gofal Cymru
Cyfeiriad y sefydliad: Caerdydd, Prydain Fawr
Dyddiad dechrau: 2017-04-01
Dyddiad gorffen: 2018-04-30
Math: grant
LAU: https://app.dimensions.ai/details/grant/grant.12902802
grant_number: CRTA-16-09 (https://europepmc.org/grantfinder/grantdetails?query=gid%3A%22CRTA-16-09%22)
Archwiliad patholegol a delweddu o anabledd cynyddol mewn sglerosis ymledol.
Sefydliad: Cyngor Ymchwil Feddygol
Cyfeiriad y sefydliad: Llundain, Prydain Fawr
Dyddiad dechrau: 2007-11-01
Dyddiad gorffen: 2009-10-31
Math: grant
LAU: https://app.dimensions.ai/details/grant/grant.13883767
grant_number: G0700584/1 (https://gtr.ukri.org/projects?ref=G0700584%2F1)
-
-
Addysgu
Rwy'n cyfrannu at addysgu niwroleg Israddedig Meddygol C21. Rwy'n diwtor clinigol i fyfyrwyr 4oed sy'n cylchdroi trwy leoliadau Niwroleg ac rwyf hefyd wedi bod yn diwtor israddedig i grŵp o fyfyrwyr1af - 2il flwyddyn ers iddynt ddechrau ar y cwrs meddygol.
Rwy'n cynnal rhaglen reolaidd o brosiectau SSC3 a 4 blynedd yn ogystal â BSc prosiectau rhyng-gyfrifedig ar gyfer y cwrs meddygol israddedig. Rydym yn derbyn adborth da yn gyson gan ein myfyrwyr ac yn mwynhau'r rhyngweithio y maent yn ei gynnig i'r adran.
Rwy'n trefnu diwrnodau addysgu a hyfforddi ar gyfer hyfforddeion Arbenigedd Niwroleg ar draws y rhanbarth ar bynciau gan gynnwys Niwropatholeg, Niwroddelweddu a Niwro-oncoleg, gyda siaradwyr gwadd ac ystod o fformatau.
Rwy'n arholwr mewn arholiadau pratical ffurfiannol a chrynodol israddedig (OSCE / ISCE).
Bywgraffiad
Swyddi academaidd a chlinigol
|
Athro |
Prifysgol Caerdydd |
Awst 2026 - presennol |
|
Darllenydd Clincial |
Prifysgol Caerdydd |
Awst 2022 - Awst 2026 |
|
Uwch Ddarlithydd Clinigol |
Prifysgol Caerdydd |
Mawrth 2018 - Awst 2022 |
|
Niwrolegydd Ymgynghorol |
Ysbyty Athrofaol Cymru |
Mawrth 2017 – Chwefror 2018 |
|
Uwch Ddarlithydd Clinigol |
Prifysgol Caerdydd |
Mawrth 2016 – Chwefror 2017 |
|
Cymrawd Ymchwil Ôl-CCT
Niwroleg SpR |
Ysbyty Athrofaol Cymru Deoniaeth Cymru |
Gorffennaf 2015 – Chwefror 2016
Awst 2012 – Gorffennaf 2015 |
|
Niwroleg SpR |
Deoniaeth Dwyrain Canolbarth Lloegr |
Awst 2009 – Awst 2012 |
Anrhydeddau a dyfarniadau
- Cymrawd Coleg Brenhinol y Meddygon
- Ysgrifennydd/ Trysorydd Gwarantwyr yr Ymennydd
Aelodaethau proffesiynol
- Aelod o Goleg Brenhinol y Meddygon
- Cymdeithas Niwroleg Prydain
- Trwydded General Medical Council i ymarfer
Pwyllgorau ac adolygu
Rwy'n adolygu llawysgrifau yn rheolaidd ar gyfer cyhoeddiad a adolygir gan gymheiriaid.
Rwy'n adolygydd ac rwyf wedi cyfweld am wobrau grant drwy Gymdeithas Niwroleg Prydain.
Rwyf hefyd wedi adolygu dyfarniadau grant i MRC ac MS Society.
Meysydd goruchwyliaeth
Mae gen i ddiddordeb mewn goruchwylio myfyrwyr PhD yn
Clefyd niwroinflammatory
Niwroddelweddu yn MS
Ymgysylltu
I am involved in public engagament via various channels. We engage with our cohort of people with neuroinflamamtory disease via regular newsletters and patient information days. We have run numerous patient and stakeholder focus groups to guide and influence our research. I was involved in patient consultation during the development of the DELIVER-MS trial, including developing video media to aid consent. We published on metholodolgy, which was considered an exemplar for contemporary clinical trial engagement. I have provided public-facing information (Q&A) sessions on Facebook and Zoom Webinar. I am part of the Inspiring the Future scheme that seeks to promote STEM subjects for children.
